NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA has issued a final local coverage determination for Castle Biosciences' DecisionDx-UM, a prognostic test for uveal melanoma.

The LCD extends coverage for the DecisionDx-UM test to assess metastatic risk for newly diagnosed uveal melanoma patients, as well as to guide surveillance and referral to medical oncology.